Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
If the individual has refractory hypertension (persistent hypertension on the maximum doses of three different classes of antihypertensive agents), involvement of the renal arteries in the aortic dissection plane should be considered.
Nearly all cell membranes in animals, plants and fungi maintain a voltage difference between the exterior and interior of the cell, called the membrane potential. A typical voltage across an animal cell membrane is −70 mV. This means that the interior of the cell has a negative voltage relative to the exterior. In most types of cells, the membrane potential usually stays fairly constant. Some types of cells, however, are electrically active in the sense that their voltages fluctuate over time. In some types of electrically active cells, including neurons and muscle cells, the voltage fluctuations frequently take the form of a rapid upward (positive) spike followed by a rapid fall. These up-and-down cycles are known as action potentials. Their duration varies considerably with the type of cell. In mammalian neurons, the entire up-and-down cycle takes only a few thousandths of a second, while in plant cells, an action potential may last as long as several seconds. The electrical properties of a cell are determined by the structure of its membrane. A cell membrane consists of a lipid bilayer of molecules in which larger protein molecules are embedded. The lipid bilayer is highly resistant to movement of electrically charged ions, so it functions as an insulator. The large membrane-embedded proteins, in contrast, provide channels through which ions can pass across the membrane. Action potentials are driven by channel proteins whose configuration switches between closed and open states as a function of the voltage difference between the interior and exterior of the cell.
Only two SSRIs are licensed for use with children in the UK, sertraline (Zoloft) and fluvoxamine (Luvox), for the treatment of obsessive–compulsive disorder. Fluoxetine is not licensed for this use. A 2007 comparison of aggression and hostility occurring during treatment with fluoxetine to placebo in children and adolescents found that no significant difference between the fluoxetine group and the placebo group. There is also evidence that higher rates of SSRI prescriptions are associated with lower rates of suicide in children, though since the evidence is correlational, the true nature of the relationship is unclear. A 2021 Swedish study, using a within-individual design, also found that young people (as well as adults) who have both attempted suicide and been prescribed SSRIs most commonly make the attempt before, rather than after, starting their SSRI prescription.
== Biuret reagent == The biuret reagent is made of sodium hydroxide (NaOH) and hydrated copper(II) sulfate, together with potassium sodium tartrate, the latter of which is added to chelate and thus stabilize the cupric ions. The reaction of the cupric ions with the nitrogen atoms involved in peptide bonds leads to the displacement of the peptide hydrogen atoms under the alkaline conditions. A tri- or tetra-dentate chelation with the peptide nitrogen produces the characteristic color. This is found with dipeptides. The reagent is commonly used in the biuret protein assay, a colorimetric test used to determine protein concentration by UV/VIS spectroscopy at wavelength 540 nm.
Sources: en.wikipedia.org
== External links == Tree Family Betulaceae Diagnostic photos of many species, Morton Arboretum specimens Eichhorn, Markus (July 2010). "The Birch Tree". Test Tube. Brady Haran for the University of Nottingham.
In chemistry, particularly in biochemistry, a fatty acid is a carboxylic acid with an aliphatic chain, which is either saturated or unsaturated. Most naturally occurring fatty acids have an unbranched chain of an even number of carbon atoms, from 4 to 28. Fatty acids are a major component of the lipids (up to 70% by weight) in some species such as microalgae but in some other organisms are not found in their standalone form, but instead exist as three main classes of esters: triglycerides, phospholipids, and cholesteryl esters. In any of these forms, fatty acids are both important dietary sources of fuel for animals and important structural components for cells.
=== Mental === A 2018 survey by the American Psychological Association revealed that Generation Z had the weakest mental health of any living generation; some 91% of this demographic cohort reported physical or emotion symptoms associated with stress. Surgeon General of the United States Vivek Murthy stated in a 2021 advisory that the shares of young people having suicidal ideation and suffering from persistent feelings of sadness or hopelessness had grown precipitously compared to the previous decade. There is a growing body of evidence that there is a direct link between having access to social media at a young age and weak mental health, especially among teenage girls. Parents who are overly involved in their children's lives are likely making matters worse by preventing their children from developing emotional resilience. Across the United States, university students are seeking mental health support. Many are discussing their distress over climate change with their psychotherapists. Compared to the 2000s, the 2010s saw a marked increase in the rate of suicide among adolescents, due to an increased willingness by families and coroners to label a death as a result of suicide, depression or opioid usage. Nadine Kaslow, a psychiatrist and behavioral scientist at the Emory University School of Medicine, pointed to the weakening of familial and other social bonds and the heavy use of modern communications technology, which exposes people to the risk of cyber-bullying. The number of American teenagers who exhibited the classic symptoms of depression jumped during the 2010s.
=== Other external data === Analysis of clinical trial data may be carried out by laboratories, image processing specialists or other third parties. The clinical data manager liaises with such data providers and agree data formats and transfer schedules. Data may be reconciled against the CRF to ensure consistency.
== Further reading == Donald, Bruce R. (2011). Algorithms in Structural Molecular Biology. Computational Molecular Biology. Cambridge, Mass.: The MIT Press. ISBN 978-0-262-01559-2. OCLC 1200909148. Jin, Wenzhen; Kambara, Ohki; Sasakawa, Hiroaki; Tamura, Atsuo & Takada, Shoji (May 2003). "De Novo Design of Foldable Proteins with Smooth Folding Funnel: Automated Negative Design and Experimental Verification". Structure. 11 (5): 581–590. doi:10.1016/S0969-2126(03)00075-3. PMID 12737823. Pokala, Navin & Handel, Tracy M. (2005). "Energy Functions for Protein Design: Adjustment with Protein–Protein Complex Affinities, Models for the Unfolded State, and Negative Design of Solubility and Specificity". Journal of Molecular Biology. 347 (1): 203–227. doi:10.1016/j.jmb.2004.12.019. PMID 15733929. Sander, Chris; Vriend, Gerrit; Bazan, Fernando; Horovitz, Amnon; Nakamura, Haruki; Ribas, Luis; Finkelstein, Alexei V.; Lockhart, Andrew; Merkl, Rainer; et al. (February 1992). "Protein Design on Computers. Five New Proteins: Shpilka, Grendel, Fingerclasp, Leather and Aida". Proteins: Structure, Function, and Bioinformatics. 12 (2): 105–110. doi:10.1002/prot.340120203. PMID 1603799. S2CID 38986245.
Sources: en.wikipedia.org
=== Regulation of intracellular signaling pathways === TGA1 also regulates intracellular signaling pathways that control tumor-associated behaviors. In retinoblastoma, ITGA1 promotes proliferation, migration, and colony formation through the activation of STAT3 signaling. ITGA1 inhibition decreases STAT3 expression, phosphorylated STAT3 activity, STAT3 nuclear localization, and focal adhesion kinase (FAK) signaling. Restoring STAT3 activity partially recovers the effects of ITGA1 suppression. Transcriptomic analysis of ITGA1-inhibited retinoblastoma cells showed altered regulation of genes involved in focal adhesion, ECM-receptor interactions, integrin signaling, and JAK-STAT pathways, indicating that ITGA1 works as a regulator of multiple signaling networks.
The epithelium of the ectocervix (the portion of the uterine cervix extending into the vagina) is an extension of, and shares a border with, the vaginal epithelium. The vaginal epithelium is made up of layers of cells, including the basal cells, the parabasal cells, the superficial squamous flat cells, and the intermediate cells. The basal layer of the epithelium is the most mitotically active and reproduces new cells. The superficial cells shed continuously and basal cells replace them. Estrogen induces the intermediate and superficial cells to fill with glycogen. Cells from the lower basal layer transition from active metabolic activity to death (apoptosis). In these mid-layers of the epithelia, the cells begin to lose their mitochondria and other organelles. The cells retain a usually high level of glycogen compared to other epithelial tissue in the body. Under the influence of maternal estrogen, the vagina of a newborn is lined by thick stratified squamous epithelium (or mucosa) for two to four weeks after birth. Between then to puberty, the epithelium remains thin with only a few layers of cuboidal cells without glycogen. The epithelium also has few rugae and is red in color before puberty. When puberty begins, the mucosa thickens and again becomes stratified squamous epithelium with glycogen-containing cells, under the influence of the girl's rising estrogen levels. Finally, the epithelium thins out from menopause onward and eventually ceases to contain glycogen, because of the lack of estrogen.
The Enzyme Function Initiative (EFI) is a large-scale collaborative project aiming to develop and disseminate a robust strategy to determine enzyme function through an integrated sequence–structure-based approach. The project was funded in May 2010 by the National Institute of General Medical Sciences as a Glue Grant which supports the research of complex biological problems that cannot be solved by a single research group. The EFI was largely spurred by the need to develop methods to identify the functions of the enormous number proteins discovered through genomic sequencing projects.
The biological value of proteins in general, hence also of grain-proteins, is fundamentally determined by the ratio between the essential amino acids to be found in cereals and the requirement of essential amino acids of the living creature, consuming protein...the most important way of raising the biological value ... [is] given by the technique of complementing. In 2011 PLOS ONE published an article investigating the specifics of protein combining for 1251 plant-based foods. The bases of reference are the amino acids indispensable to human nutrition, and the ideal proportioning of these amino acids in a meal. They explain, "complementation involves consuming two or more foods together to yield an amino acid pattern that is better than the sum of the two foods alone." In contrast to pairings based on food groups, such as pairing a grain with a bean, the investigators reported that pairing by food group was not supported by their work: "Examining the top 100 pairings for each food, we found no consistent pattern of food group-food group pairings."
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.